Gilead Places Restrictions on 340B Drug Pricing for Hepatitis C Treatments

The drugmaker Gilead cut off 340B discounts for certain hepatitis C drugs to some hospitals if they do not provide claims data to their specifications. The drugs, which include Epclusa, Solvadi, Vosevi, and Harvoni, previously qualified for 340B pricing discounts, but the manufacturer accuses safety-net hospitals of diversion and using duplicate accounts. Patient advocates say this limits access to lifesaving drugs for low-income patients, particularly in rural areas. Gilead is just one of 15 pharma companies to revoke 340B discounts to safety-net medical centers.

According to Erica Carbajal of Becker’s Hospital Review, “GlaxoSmithKline, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, UCB and United Therapeutics have all moved to stop or limit 340B discounts on drugs dispensed at community pharmacies.”

To learn more, click here.

(Source: Becker’s Hospital Review, May 16^th, 2022)